Teclistamab:靶向BCMA的T细胞重定向双特异性抗体在多发性骨髓瘤中的活性
本文报道了一种靶向BCMA和CD3的双特异性抗体teclistamab(JNJ-64007957),可在体外招募并激活T细胞杀伤BCMA阳性骨髓瘤细胞系,并在患者骨髓样本及小鼠异种移植模型中显示抗肿瘤活性,支持进一步临床评估。
要点
- Teclistamab在体外对BCMA阳性骨髓瘤细胞系具有细胞毒性并伴随T细胞激活和细胞因子释放。
- 在骨髓瘤患者骨髓样本的离体实验中,teclistamab可清除BCMA阳性细胞。
- 在两种BCMA阳性骨髓瘤小鼠异种移植模型中观察到抗肿瘤活性。
核心结论
- Teclistamab对表达BCMA的骨髓瘤细胞系、患者样本和异种移植模型具有特异且强效的活性,值得进一步评估用于多发性骨髓瘤治疗。
研究设计与样本
- 临床前研究:体外细胞系实验、患者骨髓样本离体实验、健康人全血实验及两种小鼠异种移植模型。
主要发现
- Teclistamab对H929细胞的细胞毒性EC50为0.15 nM,对MM.1R细胞为0.06 nM,对RPMI 8226细胞为0.45 nM。
- Teclistamab诱导T细胞激活的EC50:H929细胞0.21 nM,MM.1R细胞0.1 nM,RPMI 8226细胞0.28 nM。
- 在患者骨髓样本离体实验中,teclistamab清除BCMA阳性细胞的平均EC50为1.7 nM。
- 在健康人全血中,teclistamab介导对H929细胞的剂量依赖性裂解和T细胞激活。
- 在两种小鼠异种移植模型中,teclistamab显示抗肿瘤活性:H929模型肿瘤抑制,RPMI 8226模型肿瘤消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells. BCMA is highly expressed on plasmablasts and plasma cells from multiple myeloma (MM) patient samples. We developed a BCMAxCD3 bispecific antibody (teclistamab [JNJ-64007957]) to recruit and activate T cells to kill BCMA-expressing MM cells. Teclistamab induced cytotoxicity of BCMA+ MM cell lines in vitro (H929 cells, 50% effective concentration [EC50] = 0.15 nM; MM.1R cells, EC50 = 0.06 nM; RPMI 8226 cells, EC50 = 0.45 nM) with concomitant T-cell activation (H929 cells, EC50 = 0.21 nM; MM.1R cells, EC50 = 0.1 nM; RPMI 8226 cells, EC50 = 0.28 nM) and cytokine release. This activity was further increased in the presence of a γ-secretase inhibitor (LY-411575). Teclistamab also depleted BCMA+ cells in bone marrow samples from MM patients in an ex vivo assay with an average EC50 value of 1.7 nM. Under more physiological conditions using healthy human whole blood, teclistamab mediated dose-dependent lysis of H929 cells and activation of T cells. Antitumor activity of teclistamab was also observed in 2 BCMA+ MM murine xenograft models inoculated with human T cells (tumor inhibition with H929 model and tumor regression with the RPMI 8226 model) compared with vehicle and antibody controls. The specific and potent activity of teclistamab against BCMA-expressing cells from MM cell lines, patient samples, and MM xenograft models warrant further evaluation of this bispecific antibody for the treatment of MM. Phase 1 clinical trials (monotherapy, #NCT03145181; combination therapy, #NCT04108195) are ongoing for patients with relapsed/refractory MM.
引用
- Pillarisetti K, Powers G, Luistro L, et al. Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma. Blood Adv. 2020. PMID: 32956453. doi:10.1182/bloodadvances.2020002393
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。